Alkermes announced positive topline results from a phase 1 study of its new antipsychotic candidate, ALKS 3831, a combination of a proprietary drug molecule, ALKS 33, and olanzapine, a molecule that is commercially available under the name Zypreka. ALKS 3831 is in development for the treatment of schizophrenia and is designed to attenuate the antipsychotic-related metabolic side effect of weight gain. Data from the study showed that patients administered ALKS 3831 demonstrated significantly less weight gain compared to patients taking olanzapine. Based on the results, Alkermes plans to meet with the FDA and initiate a phase 2 study of ALKS 3831 in mid calendar 2013.
- Pharmaceuticals & Drug Trials